JPRN-UMIN000002603已完成未知
Phase I study of Gemtuzumab Ozogamicin given in combination with Enocitabine and Daunorubicin as induction therapy for elderly patients with acute myeloid leukemia - JALSG GML208-P1
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 65years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) History of myelodysplastic syndromes or myeloproliferative neoplasms 2) Therapy-related leukemia 3) Infiltration on central nurvous system 4) Previous autologous or allogeneic stem cell transplantation 5) History of glaucoma 6) Diabetes mellitus currently treated with insulin 7) Uncontrollable hypertension 8) History of ischemic heart disease, cardiomyopathy or arrythmia currently treated 9) Interstitial pneumonia, pulmonary fibrosis, or svere emphysema 10) Positivity of HBs antigen, HCV antibody or human immunodeficiency virus 11) Active infectious disease 12) Liver cirrhosis 13) Double cancer 14) Difficulty of treatment based on mental illness
研究者
相似试验
进行中（未招募）
1 期
Phase II Study on Gemtuzumab Ozogamicin in Combination with All-trans-Retinoic Acid, high-dose Cytarabine and Mitoxantrone in Patients with primary refractory acute myeloid leukemia [GO-A-HAM] - GO-A-HAMEUCTR2004-003739-30-ATniversitätsklinikum Ulm / University Clinical Center Ulm84
已完成
2 期
A study of gemtuzumab ozogamicin in combination with G-CSF after CAG or MEC (CA-G-GO therapy or MEC-G-GO therapy) for relapsed or refractory acute myeloid leukemia.Acute Myeloid LeukemiaJPRN-UMIN000027522Wakayama Medical University20
已完成
1 期
A Phase I study of Inotuzumab Ozogamicin as a single agent for pediatric patients in Japan with relapsed/refractory CD22-positive Acute Lymphoblastic LeukemiaRelapsed or refractory CD22-positive ALL Relapsed or refractory CD22-positive lymphoblastic lymphoma and bone marrow involvementJPRN-UMIN000033351ational Cancer Center Hospital Nagoya Medical Center Osaka City General Hospital Kyushu Cancer Center Hyogo Prefectural Kobe Children's Hospital18
进行中（未招募）
1 期
The safety and efficacy of the medicine Inotuzumab Ozogamicin in childrenwith relapsed/refractory acute lymphatic leukemia (ALL)pediatric CD22-positive relapsed/refractory Acute Lymphoblastic LeukemiaMedDRA version: 21.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864EUCTR2016-000227-71-BEErasmus Medical Center156
进行中（未招募）
1 期
The safety and efficacy of the medicine Inotuzumab Ozogamicin in children with relapsed/refractory acute lymphatic leukemia (ALL)EUCTR2016-000227-71-FIErasmus Medical Center156